Strategic Global Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.53M Buy
16,592
+1,719
+12% +$264K 0.41% 69
2025
Q4
$2.05M Buy
14,873
+1,691
+13% +$221K 0.32% 83
2025
Q3
$1.69M Sell
13,182
-1,065
-7% -$130K 0.26% 92
2025
Q2
$1.72M Buy
14,247
+1,732
+14% +$195K 0.28% 84
2025
Q1
$1.4M Sell
12,515
-296
-2% -$31.5K 0.28% 89
2024
Q4
$1.25M Buy
12,811
+920
+8% +$98.1K 0.23% 90
2024
Q3
$1.37M Buy
11,891
+6,440
+118% +$731K 0.27% 86
2024
Q2
$1.09M Sell
5,451
-5,286
-49% -$531K 0.23% 94
2024
Q1
$1.04M Sell
10,737
-103
-1% -$10.6K 0.22% 103
2023
Q4
$1.09M Sell
10,840
-250
-2% -$24.1K 0.25% 104
2023
Q3
$1.13M Sell
11,090
-756
-6% -$76.7K 0.19% 110
2023
Q2
$1.2M Sell
11,846
-234
-2% -$23.4K 0.18% 109
2023
Q1
$1.11M Buy
12,080
+7,663
+173% +$669K 0.18% 105
2022
Q4
$401K Sell
4,417
-22
-0.5% -$1.85K 0.06% 121
2022
Q3
$337K Buy
4,439
+203
+5% +$16.8K 0.06% 125
2022
Q2
$358K Sell
4,236
-65
-2% -$5.7K 0.05% 127
2022
Q1
$377K Buy
4,301
+62
+1% +$5.37K 0.06% 120
2021
Q4
$1.67M Sell
4,239
-16,912
-80% -$1.4M 0.22% 109
2021
Q3
$1.73M Sell
21,151
-59
-0.3% -$5.31K 0.25% 105
2021
Q2
$1.94M Sell
21,210
-28,939
-58% -$2.58M 0.35% 99
2021
Q1
$4.29M Buy
50,149
+125
+0.2% +$11.2K 0.77% 40
2020
Q4
$4.72M Sell
50,024
-1,727
-3% -$151K 0.83% 39
2020
Q3
$4.5M Buy
51,751
+5,692
+12% +$493K 0.85% 40
2020
Q2
$4.02M Buy
46,059
+11,062
+32% +$955K 0.86% 38
2020
Q1
$2.89M Buy
34,997
+7,588
+28% +$677K 0.74% 41
2019
Q4
$2.6M Buy
27,409
+5,119
+23% +$459K 0.54% 50
2019
Q3
$1.94M Buy
22,290
+108
+0.5% +$9.7K 0.44% 62
2019
Q2
$2.02M Sell
22,182
-2,406
-10% -$204K 0.43% 68
2019
Q1
$2.12M Buy
24,588
+19,501
+383% +$1.57M 0.45% 69
2018
Q4
$391K Sell
5,087
-657
-11% -$51.1K 0.14% 116
2018
Q3
$443K Buy
5,744
+179
+3% +$13.2K 0.13% 127
2018
Q2
$403K Hold
5,565
0.1% 139
2018
Q1
$403K Buy
5,565
+131
+2% +$9.97K 0.14% 128
2017
Q4
$409K Buy
+5,434
New +$410K 0.13% 121

Other funds holding NVS

Strategic Global Advisors's NVS Position: Q1 2026 in Review

Strategic Global Advisors increased its Novartis (NVS) stake by 12% in Q1 2026, buying an estimated $264K and bringing the position to 16,592 shares worth $2.53M. The position accounts for 0.41% of the portfolio, ranked #69.

Strategic Global Advisors first reported a position in NVS in Q4 2017 and has held it in 34 quarters since. The position peaked at $4.72M in Q4 2020. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Strategic Global Advisors held 16,592 shares of Novartis worth $2.53M as of Q1 2026.
  • Strategic Global Advisors bought 1,719 Novartis shares in Q1 2026, an estimated $264K.
  • Novartis made up 0.41% of Strategic Global Advisors's portfolio in Q1 2026, its #69 holding.
  • Strategic Global Advisors first reported a position in Novartis in Q4 2017 and has held it in 34 quarters since.
  • Strategic Global Advisors's Novartis position peaked at $4.72M in Q4 2020.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Strategic Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.